JPH11209266A - Internal liquid medicine haying reduced bitterness - Google Patents
Internal liquid medicine haying reduced bitternessInfo
- Publication number
- JPH11209266A JPH11209266A JP10009985A JP998598A JPH11209266A JP H11209266 A JPH11209266 A JP H11209266A JP 10009985 A JP10009985 A JP 10009985A JP 998598 A JP998598 A JP 998598A JP H11209266 A JPH11209266 A JP H11209266A
- Authority
- JP
- Japan
- Prior art keywords
- thiamine
- liquid medicine
- bitterness
- flavor
- internal liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000019658 bitter taste Nutrition 0.000 title claims abstract description 19
- 239000007788 liquid Substances 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 239000000796 flavoring agent Substances 0.000 claims abstract description 20
- 235000019634 flavors Nutrition 0.000 claims abstract description 20
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000019157 thiamine Nutrition 0.000 claims abstract description 18
- 229960003495 thiamine Drugs 0.000 claims abstract description 18
- 239000011721 thiamine Substances 0.000 claims abstract description 18
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 229930195733 hydrocarbon Natural products 0.000 claims abstract description 6
- 229930003658 monoterpene Natural products 0.000 claims abstract description 6
- -1 monoterpene hydrocarbon Chemical class 0.000 claims abstract description 6
- OJYLAHXKWMRDGS-UHFFFAOYSA-N zingerone Chemical compound COC1=CC(CCC(C)=O)=CC=C1O OJYLAHXKWMRDGS-UHFFFAOYSA-N 0.000 claims abstract description 6
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 claims abstract description 4
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 claims abstract description 4
- 235000002780 gingerol Nutrition 0.000 claims abstract description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000002577 monoterpenes Nutrition 0.000 claims abstract description 3
- 239000001301 oxygen Substances 0.000 claims abstract description 3
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 3
- 229930004725 sesquiterpene Natural products 0.000 claims abstract description 3
- 239000004215 Carbon black (E152) Substances 0.000 claims abstract 4
- 150000002773 monoterpene derivatives Chemical class 0.000 claims abstract 2
- 238000002360 preparation method Methods 0.000 claims description 15
- 241000234314 Zingiber Species 0.000 claims description 10
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 10
- 239000003205 fragrance Substances 0.000 claims description 10
- 235000008397 ginger Nutrition 0.000 claims description 10
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 claims description 3
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 claims description 3
- 239000002304 perfume Substances 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 239000000284 extract Substances 0.000 description 12
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 235000014080 ginger ale Nutrition 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 6
- 239000001630 malic acid Substances 0.000 description 6
- 235000011090 malic acid Nutrition 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- AEDORKVKMIVLBW-BLDDREHASA-N 3-oxo-3-[[(2r,3s,4s,5r,6r)-3,4,5-trihydroxy-6-[[5-hydroxy-4-(hydroxymethyl)-6-methylpyridin-3-yl]methoxy]oxan-2-yl]methoxy]propanoic acid Chemical compound OCC1=C(O)C(C)=NC=C1CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)CC(O)=O)O1 AEDORKVKMIVLBW-BLDDREHASA-N 0.000 description 5
- OHSHFZJLPYLRIP-BMZHGHOISA-M Riboflavin sodium phosphate Chemical compound [Na+].OP(=O)([O-])OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O OHSHFZJLPYLRIP-BMZHGHOISA-M 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229960001948 caffeine Drugs 0.000 description 5
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 5
- 229960003966 nicotinamide Drugs 0.000 description 5
- 235000005152 nicotinamide Nutrition 0.000 description 5
- 239000011570 nicotinamide Substances 0.000 description 5
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000004299 sodium benzoate Substances 0.000 description 4
- 235000010234 sodium benzoate Nutrition 0.000 description 4
- 229940045613 taurine 1000 mg Drugs 0.000 description 4
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229940089782 pyridoxine hydrochloride 5 mg Drugs 0.000 description 3
- 229950001574 riboflavin phosphate Drugs 0.000 description 3
- JXXCENBLGFBQJM-UHFFFAOYSA-N (3-carboxy-2-hydroxypropyl)-trimethylazanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC(O)CC(O)=O JXXCENBLGFBQJM-UHFFFAOYSA-N 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 229940089808 pyridoxine hydrochloride 10 mg Drugs 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 241000336315 Cistanche salsa Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 235000019596 Masking bitterness Nutrition 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 241000340987 Ptychopetalum olacoides Species 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- XMXOIHIZTOVVFB-JIZZDEOASA-L disodium;(2s)-2-aminobutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CC([O-])=O XMXOIHIZTOVVFB-JIZZDEOASA-L 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229940064880 inositol 100 mg Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000010813 municipal solid waste Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- KKOXKGNSUHTUBV-UHFFFAOYSA-N racemic zingiberene Natural products CC(C)=CCCC(C)C1CC=C(C)C=C1 KKOXKGNSUHTUBV-UHFFFAOYSA-N 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229940086388 thiamine hydrochloride 5 mg Drugs 0.000 description 1
- 150000003544 thiamines Chemical class 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- KKOXKGNSUHTUBV-LSDHHAIUSA-N zingiberene Chemical compound CC(C)=CCC[C@H](C)[C@H]1CC=C(C)C=C1 KKOXKGNSUHTUBV-LSDHHAIUSA-N 0.000 description 1
- 229930001895 zingiberene Natural products 0.000 description 1
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、風味が改善された
内服液剤に関する。TECHNICAL FIELD The present invention relates to an oral liquid preparation having an improved flavor.
【0002】[0002]
【従来の技術】チアミンは様々な薬効が知られ、医薬
品、食品などに広く配合されている。しかし、内服液剤
にチアミンを配合した場合、その独特の苦味のため風味
に満足できなかった。チアミンの苦味改善のために種々
の方法が提案されているが、満足できるものはなかっ
た。2. Description of the Related Art Thiamine is known for its various medicinal effects and is widely used in medicines, foods and the like. However, when thiamine was added to the liquid for oral administration, the flavor was not satisfactory due to its unique bitterness. Various methods have been proposed for improving the bitterness of thiamine, but none have been satisfactory.
【0003】[0003]
【発明が解決しようとする課題】本発明は、チアミン配
合内服液剤の風味の改善を目的とする。An object of the present invention is to improve the flavor of a thiamine-containing oral liquid preparation.
【0004】[0004]
【課題を解決するための手段】本発明者らは種々検討し
た結果、ジンジャー系の香料がチアミンの苦味を特異的
に低減させることを見出し、本発明を完成した。As a result of various studies, the present inventors have found that a ginger-based fragrance specifically reduces the bitterness of thiamine, and have completed the present invention.
【0005】すなわち本発明はチアミンまたはその塩を
配合した液剤において、ジンジャー系香料を添加するこ
とにより苦味が低減された内服液剤である。[0005] That is, the present invention relates to a liquid preparation containing thiamine or a salt thereof, in which bitterness is reduced by adding a ginger-based flavor.
【0006】本発明の効果は、ジンジャー系香料の、柑
橘系香料様のトップノートおよび独特の辛みを呈するボ
ディーノートを併せ持つ性質が、チアミンの苦味と重な
ったことにより生じるものと推測される。[0006] The effect of the present invention is presumed to be caused by the fact that the ginger-based flavor combines the citrus flavor-like top note and the body note exhibiting unique spiciness with the bitterness of thiamine.
【0007】[0007]
【発明の実施の形態】本発明でチアミンの塩とは、塩と
したときにも実質的にチアミンと同様の苦味を有するも
のである。具体的に本発明が適用される塩としては硝酸
塩および塩酸塩などをあげることができる。BEST MODE FOR CARRYING OUT THE INVENTION In the present invention, a thiamine salt has substantially the same bitterness as thiamine when converted into a salt. Specifically, the salts to which the present invention is applied include nitrates and hydrochlorides.
【0008】チアミンまたはその塩の配合量は一般的に
液剤全体の0.004〜0.02W/V%であり、本発明
はその範囲であれば苦味を低減させることができる。The amount of thiamine or a salt thereof is generally 0.004 to 0.02 W / V% of the whole liquid preparation, and the present invention can reduce bitterness within the range.
【0009】本発明で用いるジンジャー系香料として
は、ジンジャー香料、ジンジャエール香料などをあげる
ことができる。The ginger-based flavor used in the present invention includes ginger flavor, ginger ale flavor and the like.
【0010】本発明で用いるジンジャー系香料は、一般
的には香料製剤中の0.5〜5重量%の実質香気成分と
95〜99.5重量%の溶媒成分から成り立っている。The ginger-based fragrance used in the present invention generally comprises 0.5 to 5% by weight of a substantial fragrance component and 95 to 99.5% by weight of a solvent component in a fragrance preparation.
【0011】ジンジャー系香料の実質香気成分は、モノ
テルペン炭化水素、含酸素モノテルペノイドおよびセス
キテルペン炭化水素を必須成分として含有し、さらにジ
ンゲロン、ショーガオールおよびジンゲロールからなる
群から選ばれる1種または2種以上を含有するものが好
ましく、特に好ましいものは、実質香気成分のうちα−
ピネンを0.5〜5重量%、ジンジベレンを10〜50
重量%含み、ジンゲロン、ショーガオールおよびジンゲ
ロールからなる群から選ばれる1種または2種以上を痕
跡量であっても含有するものである。[0011] The substantial odor component of the ginger perfume contains monoterpene hydrocarbons, oxygen-containing monoterpenoids and sesquiterpene hydrocarbons as essential components, and is one or two selected from the group consisting of gingerone, shogaol and gingerol. Those containing at least one species are preferred, and particularly preferred are α-
0.5-5% by weight of pinene and 10-50 of Zingiberene
%, And one or more selected from the group consisting of zingerone, shogaol and gingerol even in trace amounts.
【0012】香料の配合量は、香料の実質香気成分の含
有量により異なるが、一般的にはチアミン1重量部に対
して5〜80重量部が好ましく、10〜30重量部がさ
らに好ましい。Although the amount of the fragrance varies depending on the content of the substantial fragrance component of the fragrance, it is generally preferably from 5 to 80 parts by weight, more preferably from 10 to 30 parts by weight, per part by weight of thiamine.
【0013】本発明の内服液剤は、苦味の改善効果の点
からpH2〜6が好ましく、pH2〜4の範囲が特に好
ましい。pHの調節には、一般的なpH調節剤を使用す
ることができるが、リン酸、クエン酸またはリンゴ酸が
特に好ましい。The oral liquid preparation of the present invention preferably has a pH of 2 to 6, and particularly preferably has a pH of 2 to 4, from the viewpoint of improving bitterness. For adjusting the pH, a general pH adjuster can be used, but phosphoric acid, citric acid or malic acid is particularly preferred.
【0014】本発明の内服液剤は甘味剤、他のビタミン
剤、生薬抽出物、アミノ酸類などの成分を配合すること
ができ、液剤製造の通常の方法により製造することがで
きる。The oral liquid preparation of the present invention can contain components such as sweeteners, other vitamin preparations, crude drug extracts, amino acids and the like, and can be produced by a usual method for producing liquid preparations.
【0015】[0015]
【発明の効果】本発明により、チアミンの苦味が改善さ
れた内服液剤が得られるので、コンプライアンスが向上
した内服液剤を提供することが可能になった。According to the present invention, an oral solution having an improved thiamine bitterness can be obtained, so that an oral solution having improved compliance can be provided.
【0016】[0016]
【実施例】以下に、実施例および試験例により本発明を
詳細に説明する。なお、実施例で用いたジンジャーエー
ル香料は実質香気成分1.0重量%のものを用いた。The present invention will be described below in detail with reference to examples and test examples. In addition, the ginger ale flavor used in the examples had a substantial flavor component of 1.0% by weight.
【0017】実施例1 チアミンを0.02W/V%およびジンジャーエール香料
が0.1W/V%となる様に精製水で溶解し、リン酸およ
び水酸化ナトリウムによりpH=3に調節し液剤を得
た。Example 1 Thiamine was dissolved in purified water so that 0.02 W / V% and ginger ale flavor became 0.1 W / V%, pH was adjusted to 3 with phosphoric acid and sodium hydroxide, and the solution was prepared. Obtained.
【0018】実施例2 チアミン0.02W/V%、シゴカ乾燥エキス0.24W/V
%(原生薬換算濃度0.48W/V%)、ニクジュヨウエ
キス0.18W/V%(原生薬換算濃度0.6W/V%)、ク
コシ流エキス0.6W/V%(原生薬換算濃度0.6W/V
%)、ゴミシ流エキス0.3W/V%(原生薬換算濃度
0.3W/V%)、ジンジャーエール香料0.1W/V%とな
る様に精製水で溶解し、リン酸および水酸化ナトリウム
によりpH=3に調節し液剤を得た。Example 2 Thiamine 0.02 W / V%, Sigoka dried extract 0.24 W / V
% (Concentration in crude drug equivalent: 0.48 W / V%), Cistanche salsa extract 0.18 W / V% (concentration in crude drug equivalent: 0.6 W / V%), Kokushi flow extract 0.6 W / V% (conversion in crude drug) Concentration 0.6W / V
%), Mashed juice extract 0.3W / V% (concentration of crude drug equivalent 0.3W / V%), ginger ale flavor 0.1W / V% dissolved in purified water, phosphoric acid and sodium hydroxide Was adjusted to pH = 3 to obtain a liquid preparation.
【0019】比較例1 実施例1から香料を除いた処方で同様にして液剤を得
た。Comparative Example 1 A liquid preparation was obtained in the same manner as in Example 1 except that the fragrance was omitted.
【0020】比較例2 実施例1の香料を、ミックスフルーツ香料1.0W/V%
に変更し、同様にして液剤を得た。COMPARATIVE EXAMPLE 2 The flavor of Example 1 was mixed with a mixed fruit flavor at 1.0 W / V%.
And a liquid preparation was obtained in the same manner.
【0021】試験例1 実施例および比較例の水溶液について、20名の専門パ
ネルにより苦味の程度を官能評価試験の1つ二元配置法
により評価した。Test Example 1 With respect to the aqueous solutions of Examples and Comparative Examples, the degree of bitterness was evaluated by a two-way arrangement method in a sensory evaluation test by a specialized panel of 20 persons.
【0022】苦味の評価は、以下に示した5段階とし、
A:2、B:4、C:6、D:8、E:10ポイントと
して平均苦味マスキングポイントを算出した。試験結果
を表1に示した。The evaluation of bitterness is made in the following five stages,
The average bitterness masking point was calculated as A: 2, B: 4, C: 6, D: 8, E: 10 points. The test results are shown in Table 1.
【0023】 A:不快で、強烈な苦味を感じ、非常に飲みづらい B:不快な苦味を感じ、飲みづらい C:やや不快な苦味を感じるが、飲用に苦痛や抵抗はな
い D:微妙に苦味は感じるが、飲用に苦痛や抵抗はない E:苦味を感じず、飲みやすいA: unpleasant, intense bitterness, very difficult to drink B: unpleasant bitterness, difficult to drink C: somewhat unpleasant bitterness, but no pain or resistance to drinking D: subtle bitterness Feel, but no pain or resistance to drinking E: No bitterness, easy to drink
【0024】[0024]
【表1】 [Table 1]
【0025】また、二元配置法の分散分析による解析結
果およびスチューデント検定の結果を表2および図1に
示した。Table 2 and FIG. 1 show the analysis results by the two-way analysis of variance and the results of the student test.
【0026】[0026]
【表2】 [Table 2]
【0027】実施例3 チアミン硝酸塩 5mg リン酸リボフラビンナトリウム 5mg ピリドキシン塩酸塩 5mg イノシトール 50mg 無水カフェイン 50mg タウリン 1000mg ニコチン酸アミド 20mg ショ糖 10g マルチトール 2g 安息香酸ナトリウム 60mg ジンジャーエール香料 100mg 精製水 (全量)100mL 上記処方を混合溶解し、クエン酸およびリンゴ酸でpH
=3に調節した。Example 3 Thiamine nitrate 5 mg Riboflavin sodium phosphate 5 mg Pyridoxine hydrochloride 5 mg Inositol 50 mg Anhydrous caffeine 50 mg Taurine 1000 mg Nicotinamide 20 mg Sucrose 10 g Maltitol 2 g Sodium benzoate 60 mg Ginger ale flavor 100 mg Purified water 100 mL Mix and dissolve the above formulation, pH with citric acid and malic acid
= 3.
【0028】実施例4 チアミン塩酸塩 5mg リン酸リボフラビンナトリウム 5mg ピリドキシン塩酸塩 5mg イノシトール 50mg 無水カフェイン 50mg タウリン 1000mg ニコチン酸アミド 20mg ショ糖 10g マルチトール 2g 安息香酸ナトリウム 60mg ジンジャーエール香料 100mg 精製水 (全量)100mL 上記処方を混合溶解し、クエン酸およびリンゴ酸でpH
=3に調節した。Example 4 Thiamine hydrochloride 5 mg Sodium riboflavin phosphate 5 mg Pyridoxine hydrochloride 5 mg Inositol 50 mg Anhydrous caffeine 50 mg Taurine 1000 mg Nicotinamide 20 mg Sucrose 10 g Maltitol 2 g Sodium benzoate 60 mg Ginger ale flavor 100 mg Purified water (total amount) 100mL Mix and dissolve the above formulation, pH with citric acid and malic acid
= 3.
【0029】実施例5 チアミン硝酸塩 7mg リン酸リボフラビンナトリウム 5mg ピリドキシン塩酸塩 5mg シゴカ乾燥エキス 25mg (原生薬換算600mg) ニクジュヨウエキス 180mg (原生薬換算600mg) ゴミシ流エキス 300μL (原生薬換算600mg) トウチュウカソウ流エキス 150μL (原生薬換算150mg) DL−塩化カルニチン 50mg イノシトール 100mg 無水カフェイン 50mg タウリン 2000mg ニコチン酸アミド 30mg ショ糖 10g 70%ソルビトール溶液 2500mg ポビドン K30 1000mg 安息香酸ナトリウム 60mg ジンジャーエール香料 100mg 精製水 (全量)100mL 上記処方を混合溶解し、クエン酸およびリンゴ酸でpH
=3に調節した。Example 5 Thiamine nitrate 7 mg Riboflavin sodium phosphate 5 mg Pyridoxine hydrochloride 5 mg Shigoka dried extract 25 mg (600 mg of crude drug equivalent) Citrus extract 180 mg (600 mg of crude drug equivalent) 300 μL of trash extract (600 mg of crude drug equivalent) Flue extract 150 μL (150 mg in terms of crude drug) DL-carnitine chloride 50 mg Inositol 100 mg Anhydrous caffeine 50 mg Taurine 2000 mg Nicotinamide 30 mg Sucrose 10 g 70% sorbitol solution 2500 mg Povidone K30 1000 mg Sodium benzoate 60 mg Ginger ale perfume 100 g 100mL Mix and dissolve the above formulation, pH with citric acid and malic acid
= 3.
【0030】実施例6 チアミン硝酸塩 5mg リン酸リボフラビンナトリウム 2mg ピリドキシン塩酸塩 10mg DL−塩化カルニチン 100mg 無水カフェイン 50mg タウリン 1000mg ニコチン酸アミド 30mg L−アスパラギン酸ナトリウム 125mg コンドロイチン硫酸ナトリウム 120mg ショ糖 10g ステビア 25mg 安息香酸ナトリウム 60mg ジンジャーエール香料 100mg 精製水 (全量)100mL 上記処方を混合溶解し、クエン酸およびリンゴ酸でpH
=3に調節した。Example 6 Thiamine nitrate 5 mg Sodium riboflavin phosphate 2 mg Pyridoxine hydrochloride 10 mg DL-carnitine chloride 100 mg Anhydrous caffeine 50 mg Taurine 1000 mg Nicotinamide 30 mg L-sodium aspartate 125 mg Chondroitin sulfate 120 mg Sucrose 10 mg Stevia 25 mg Benzoate Sodium 60mg Ginger ale flavor 100mg Purified water (total) 100mL Mix and dissolve the above formulation, pH with citric acid and malic acid
= 3.
【0031】実施例7 チアミン硝酸塩 10mg リン酸リボフラビンナトリウム 5mg ピリドキシン塩酸塩 10mg クコシ流エキス 600μL (原生薬換算600mg) トウチュウカソウ流エキス 150μL (原生薬換算150mg) ムイラプアマエキス 15mg (原生薬換算300mg) DL−塩化カルニチン 100mg 無水カフェイン 50mg タウリン 1000mg ニコチン酸アミド 30mg L−アスパラギン酸ナトリウム 125mg コンドロイチン硫酸ナトリウム 120mg ショ糖 15g ステビア 25mg 安息香酸ナトリウム 60mg ジンジャーエール香料 100mg 精製水 (全量)100mL 上記処方を混合溶解し、クエン酸およびリンゴ酸でpH
=3に調節した。Example 7 Thiamine Nitrate 10 mg Riboflavin Sodium Phosphate 5 mg Pyridoxine Hydrochloride 10 mg Kukoshi Flow Extract 600 μL (prototype equivalent 600 mg) Eucalyptus Flow Extract 150 μL (prototype conversion 150 mg) Muirapuama Extract 15 mg (prototype conversion 300 mg) DL-chloride Carnitine 100mg Anhydrous caffeine 50mg Taurine 1000mg Nicotinamide 30mg Sodium L-aspartate 125mg Sodium chondroitin sulfate 120mg Sucrose 15g Stevia 25mg Sodium benzoate 60mg Ginger ale flavor 100mg Purified water (all amounts) 100mL And pH with malic acid
= 3.
【図1】 二元配置法によるマスキング試験の解析結果
を示した図である。図中(*)は5%有意水準で実施例
1、2が比較例よりも優れていることを意味している。FIG. 1 is a diagram showing an analysis result of a masking test by a two-way arrangement method. In the figure, (*) indicates that Examples 1 and 2 are superior to Comparative Example at the 5% significance level.
Claims (4)
いて、ジンジャー系香料を添加することにより苦味が低
減された内服液剤。1. A liquid preparation containing thiamine or a salt thereof, wherein the bitterness is reduced by adding a ginger-based flavor.
香料からなる内服液剤。2. An oral liquid preparation comprising thiamine or a salt thereof and a ginger-based flavor.
素、含酸素モノテルペノイドおよびセスキテルペン炭化
水素を必須成分として含有し、さらにジンゲロン、ショ
ーガオールおよびジンゲロールからなる群から選ばれる
1種または2種以上を含有した香料である請求項1また
は2に記載の内服液剤。3. A ginger-based fragrance comprising a monoterpene hydrocarbon, an oxygen-containing monoterpenoid and a sesquiterpene hydrocarbon as essential components, and one or more selected from the group consisting of gingerone, shogaol and gingerol. The liquid preparation for oral administration according to claim 1 or 2, which is a fragrance contained.
〜3のいずれかに記載の内服液剤。4. The solution according to claim 1, wherein the pH of the solution is in the range of 2 to 6.
The liquid medicine for oral administration according to any one of claims 1 to 3.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10009985A JPH11209266A (en) | 1998-01-22 | 1998-01-22 | Internal liquid medicine haying reduced bitterness |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10009985A JPH11209266A (en) | 1998-01-22 | 1998-01-22 | Internal liquid medicine haying reduced bitterness |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11209266A true JPH11209266A (en) | 1999-08-03 |
Family
ID=11735187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10009985A Pending JPH11209266A (en) | 1998-01-22 | 1998-01-22 | Internal liquid medicine haying reduced bitterness |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH11209266A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2380936A (en) * | 2001-10-18 | 2003-04-23 | Reckitt Benckiser Healthcare | Pharmaceutical composition in which the bitter taste of the active ingredient is masked |
JP2008050349A (en) * | 2006-07-25 | 2008-03-06 | Taisho Pharmaceutical Co Ltd | Beverage comprising branched-chain amino acid formulated therein |
JPWO2012005349A1 (en) * | 2010-07-09 | 2013-09-05 | サントリー食品インターナショナル株式会社 | Carbonated drink containing caffeine |
JP2013213001A (en) * | 2012-03-30 | 2013-10-17 | Arimento Kogyo Kk | Oxidation-controlling composition and solid oral agent or solid food |
-
1998
- 1998-01-22 JP JP10009985A patent/JPH11209266A/en active Pending
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2380936A (en) * | 2001-10-18 | 2003-04-23 | Reckitt Benckiser Healthcare | Pharmaceutical composition in which the bitter taste of the active ingredient is masked |
GB2380936B (en) * | 2001-10-18 | 2003-07-09 | Reckitt Benckiser Healthcare | Improvements in or relating to compositions |
AU2002330645B2 (en) * | 2001-10-18 | 2008-12-18 | Reckitt Benckiser Healthcare (Uk) Limited | Composition comprising paracetamol and a bitterness masking component |
JP2008050349A (en) * | 2006-07-25 | 2008-03-06 | Taisho Pharmaceutical Co Ltd | Beverage comprising branched-chain amino acid formulated therein |
JPWO2012005349A1 (en) * | 2010-07-09 | 2013-09-05 | サントリー食品インターナショナル株式会社 | Carbonated drink containing caffeine |
JP2013213001A (en) * | 2012-03-30 | 2013-10-17 | Arimento Kogyo Kk | Oxidation-controlling composition and solid oral agent or solid food |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4726269B2 (en) | Oral solution | |
DE112006001234T5 (en) | Method and composition for the treatment of ARG | |
JPS60218314A (en) | Vitamin aerosol composition and vitamin administration | |
JP4051717B2 (en) | Biotin-containing oral solution | |
JP3188073B2 (en) | Drinking liquid composition | |
KR20020018675A (en) | Method and Composition for Masking Mineral Taste | |
JP4190769B2 (en) | Oral liquid composition | |
JPH0458452B2 (en) | ||
JP4843837B2 (en) | Thiamine derivative-containing composition | |
JPH11209266A (en) | Internal liquid medicine haying reduced bitterness | |
US4970240A (en) | Fruity flavored nasal decongestant composition | |
JPH07227256A (en) | Liquid agent for oral administration | |
JP2003073284A (en) | Liquid composition | |
JP4622006B2 (en) | Iron compound-containing oral solution composition | |
JP2001031562A (en) | Liquid preparation for internal use | |
JP4959864B2 (en) | Glutamate-containing solution | |
JP4940492B2 (en) | Iron compound combination oral solution | |
JP4216916B2 (en) | Drinking liquid composition | |
JP4789292B2 (en) | Oral solution with improved flavor | |
JP2000169385A (en) | Internal liquid pharmaceutical preparation | |
JPH0473411B2 (en) | ||
JP2000226327A (en) | Oral liquid formulation | |
JPH1036252A (en) | Oral liquid medicine combined with belladonna (total) alkaloid | |
WO2011148794A1 (en) | Dimemorfan-containing liquid preparation for internal administration | |
JP2000239153A (en) | Internal medicine composition containing iron compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050112 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081007 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090224 |